The trial targets Acute Myeloid Leukemia (AML) in patients who are relapsed/refractory, in remission with MRD, or newly diagnosed with TP53-mutated MDS/AML.

Researchers at MUSC Hollings Cancer Center have identified a signaling loop involved in the growth and persistence of ...

Although treatment with high-dose corticosteroids can reduce mast burden and improve symptoms such as pain, congestive heart failure, and cytopenia in patients with MCL, their effects are frequently ...

Cero will use Invivoscribe's multiparametric flow cytometry assay to detect minimal residual disease in patients and evaluate the therapy's efficacy.

June marks AML Awareness Month. It is a time to understand acute myeloid leukaemia. AML is a blood cancer needing quick action. Early signs like fatig ...

The FDA has accepted the sNDA for decitabine/cedazuridine plus venetoclax to treat adults with newly diagnosed AML who are ineligible for intensive induction chemotherapy.

A new study by Indiana University School of Medicine researchers has revealed a breakthrough in the fight against acute myeloid leukemia, one of the most aggressive and fatal blood cancers in adults.

MUSC researchers at the Hollings Cancer center are making strides in new developments for leukemia treatment.Sophie Paczesny, ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

A panelist discusses how ASCO 2025's most important breakthrough was the oral decitabine plus venetoclax combination, ...